Fwd: The Business of BioBanking - View Preliminary Agenda

FYI

---------- Forwarded message ----------
From: Nicole Proulx <nicolel@healthtech.com>
Date: Tue, Jul 27, 2010 at 12:53 PM
Subject: The Business of BioBanking - View Preliminary Agenda
To: Marshall <marshall@science.uva.nl>


    <http://www.healthtech.com/bnk>


The Business of BioBanking
December 6-8, 2010 | Providence, RI
healthtech.com/bnk <http://www.healthtech.com/bnk>

  *>* Print the preliminary
agenda<http://ckt.thebiotech.net/ckt/BNK/BNS_prelim.asp?EMAIL=marshall@science.uva.nl>

> Register now and save! <https://chidb.com/register/2010/bnk/reg.asp>

*>* View The SCIENCE of
BioBanking<http://ckt.thebiotech.net/ckt/BNK/BNS_prelim.asp?EMAIL=marshall@science.uva.nl>
 co-located meeting agenda

As biobank repositories grow, the pressure increases
for standardization, documentation, protocols, and
preservation procedures to efficiently produce the best
quality product. In addition, "omics" has complicated
the direction of biomedical research, and those managers
involved must now negotiate the regulatory, ethical, and
legal issues involved in the preservation and use of
biospecimens.

Benefiting BioBank & BioRepository Managers
& Directors Through:

   - = Navigating Change
   - = Lessons Learned
   - = Value Added BioBanking
   - = Investing in the Future
   - = Creating and Maintaining Partnerships

   *Pre-Conference Short Courses** - Monday, December 6

SC1: Biostabilization of Biospecimens *View
details*<http://www.healthtech.com/Conferences_Overview.aspx?id=100547>
*

Alptekin Aksan, Ph.D., Assistant Professor, Mechanical
Engineering, University of Minnesota

**Allison Hubel, Ph.D., Professor and Director,
Biopreservation Core Resource, University of Minnesota*

SC2: Transitioning a Biobanking Effort with Scientific
and Fiscal Responsibility: Creating a Model for Both
Academic and Industry Programs *View details*
<http://www.healthtech.com/Conferences_Overview.aspx?id=100547>*
Andrew Brooks, Ph.D., Director of Operations, Rutgers
University Cell and DNA Repository; Associate Professor,
Genetics, Rutgers University

* Separate registration required.*






*Plenary Opening Session: Managing Change*

*Changing the Paradigm for Biobanking in the U.S.*
Helen M. Moore, Ph.D., Director, Biospecimen Research Network, Office of
Biorepositories and Biospecimen Research,
Office of the Director, National Cancer Institute

*A New Concept for Networking Clinical Biobanks to Overcome Barriers of
Language, Standardization, and Even the "My Syndrome"
*Peter Riegman, Ph.D., Tissue Resource Manager, Erasmus MC Tissue Bank;
Coordinator, European Human Frozen Tumor
Tissue Bank (Tubafrost); President, ISBER; Department of Pathology, Erasmus
Medical Center

*Planning and Integration of Biospecimen Collection in Clinical and
Epidemiology Trials*
Stephen M. Hewitt, M.D., Ph.D., Clinical Investigator, Laboratory of
Pathology, NCI

*Experiences from a Next-Generation Sequencing Laboratory
*William Farmerie, Ph.D., Associate Director, Interdisciplinary Center for
Biotechnology Research, University of Florida

*BioBank Management: Experience Makes the Difference*

*Lessons Learned in Biobanking at the Marshfield Clinic*
Cathy McCarty, Ph.D., M.P.H., Senior Research Scientist, Center for Human
Genetics, Marshfield Clinic Research Foundation

*Business of Biobanking: Perspective from a CRO Central Lab
*Barbara E. Glazer, MT(ASCP), Director, Pre-Analytical Services, Global
Central Laboratories, Quintiles

*Biobanking and Biospecimen Processing at the Mayo Clinic
*W. Edward Highsmith, Jr., Ph.D., Co-Director, Molecular Genetics
Laboratory, Mayo Clinic

*The Challenges of Multiuser Repositories for Disease Research*
Jay Tischfield, Ph.D., Professor, Genetics, Rutgers University; Lead
Investigator, NIDA Repository

*Biobanking and Biospecimen Processing at the Mayo Clinic*
W.Edward Highsmith, Jr., Ph.D., Co-Director, Molecular Genetics Laboratory,
Mayo Clinic

*Technologies for Value Added BioBanking*

*The International Serious Adverse Events Consortium - A Case Study of an
Innovative and Successful International Effort to Bank
and Research the Genetic Basis of Drug Related Serious Adverse Events
*Arthur Holden, Chairman and CEO, iSAEC

*Contemporary Access to Historical Biospecimen Collections*
Kevin Meager, Vice President, Information Management Services, Inc.

*Investing in the Future: Quality Products*

*Navigating the Road of Regulations*
Claudia Buser, Ph.D., Director, Global Cell Banking & Technology
Development, Genzyme Corp. (tentative)

*Building a New State-of-the-Art Tissue/Banking Facility*
Daniel Powell, Ph.D., Research Assistant, Professor, Pathology, Laboratory
Medicine, Obstetrics and Gynecology, University
of Pennsylvania (tentative)

*Why Are Prospective Clinicopathological Data as Important as Specimens?
*Iman Osman, M.D., Director, Interdisciplinary Melanoma Program, New York
University Langone Medical Center

*Plenary Closing Session: BioBanker and BioUser Partnerships*

*Millennium Presentation*
Erik Koenig, Senior Manager, Molecular Technologies, MILLENNIUM: The Takeda
Oncology Company

*Yale University Co-Presentation*
Alexander Vortmeyer, Ph.D., Director, Fresh and Frozen Tissue Procurement
and Distribution, Yale University (tentative)

*The Broad Institute Co-Presentation*
Kristin Ardlie, Director, Biological Samples Program (invited)

 ------------------------------

  *Limited speaking opportunities are still available.*

For more information, please contact:
Mary Ann Brown, Executive Conference Producer
781-972-5497 | mabrown@healthtech.com

*Interested in Sponsoring or Exhibiting?*
To find out  about our comprehensive sponsorship and
exhibit packages, contact:


Jon Stroup, Manager, Business Development
781-972-5483 | jstroup@healthtech.com

 www.healthtech.com/bns  | Register now and
save!<https://chidb.com/register/2010/bnk/reg.asp>



CHI, 250 First Avenue, Suite 300, Needham, Massachusetts 02494

This email communication is for commercial purposes. If it is not of
interest to you, please disregard and we apologize for any
inconvenience this may have caused. To prevent further emails, go to
www.chicorporate.com/corporate_unsubscribe.aspx